<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="prp21186" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmacol Res Perspect</journal-id><journal-id journal-id-type="iso-abbrev">Pharmacol Res Perspect</journal-id><journal-id journal-id-type="pmc-domain-id">2563</journal-id><journal-id journal-id-type="pmc-domain">pharmrespersp</journal-id><journal-id journal-id-type="publisher-id">PRP2</journal-id><journal-title-group><journal-title>Pharmacology Research &amp; Perspectives</journal-title></journal-title-group><issn pub-type="epub">2052-1707</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10955330</article-id><article-id pub-id-type="pmcid-ver">PMC10955330.1</article-id><article-id pub-id-type="pmcaid">10955330</article-id><article-id pub-id-type="pmcaiid">10955330</article-id><article-id pub-id-type="pmid">38511246</article-id><article-id pub-id-type="doi">10.1002/prp2.1186</article-id><article-id pub-id-type="publisher-id">PRP21186</article-id><article-id pub-id-type="other">PRP2-2023-12-0462.R1</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Synthesis of salcaprozate sodium and its significance in enhancing pancreatic kininogenase absorption performance</article-title><alt-title alt-title-type="left-running-head">Lv et&#160;al.</alt-title></title-group><contrib-group><contrib id="prp21186-cr-0001" contrib-type="author"><name name-style="western"><surname>Lv</surname><given-names initials="Z">Zhong</given-names></name><xref rid="prp21186-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="prp21186-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="prp21186-cr-0002" contrib-type="author"><name name-style="western"><surname>Luo</surname><given-names initials="QD">Qian&#8208;Dong</given-names></name><xref rid="prp21186-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="prp21186-cr-0003" contrib-type="author"><name name-style="western"><surname>Tang</surname><given-names initials="ZY">Zhang&#8208;Yong</given-names></name><xref rid="prp21186-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="prp21186-cr-0004" contrib-type="author"><name name-style="western"><surname>Lv</surname><given-names initials="XH">Xiao&#8208;Hu</given-names></name><xref rid="prp21186-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="prp21186-cr-0005" contrib-type="author"><name name-style="western"><surname>Wu</surname><given-names initials="T">Tao</given-names></name><xref rid="prp21186-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="prp21186-cr-0006" contrib-type="author"><name name-style="western"><surname>Huang</surname><given-names initials="LK">Ling&#8208;Kai</given-names></name><xref rid="prp21186-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="prp21186-cr-0007" contrib-type="author" corresp="yes"><name name-style="western"><surname>Tang</surname><given-names initials="C">Can</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0005-3370-3364</contrib-id><xref rid="prp21186-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="prp21186-aff-0006" ref-type="aff">
<sup>6</sup>
</xref><address><email>tc_tangcan88@126.com</email></address></contrib></contrib-group><aff id="prp21186-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">School of Pharmacy</named-content>
<institution>Chengdu Medical College</institution>
<city>Chengdu</city>
<country country="CN">China</country>
</aff><aff id="prp21186-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Research</named-content>
<institution>Chengdu Pu Kang Wei Xin Biotechnology Co., Ltd</institution>
<city>Chengdu</city>
<country country="CN">China</country>
</aff><aff id="prp21186-aff-0003">
<label>
<sup>3</sup>
</label>
<institution>Chengdu Pu Kang Wei Xin Biotechnology Co., Ltd</institution>
<city>Chengdu</city>
<country country="CN">China</country>
</aff><aff id="prp21186-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Research</named-content>
<institution>Debor (Chengdu) Biotechnology Co., Ltd</institution>
<city>Chengdu</city>
<country country="CN">China</country>
</aff><aff id="prp21186-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Department of Quality</named-content>
<institution>Chengdu Pu Kang Wei Xin Biotechnology Co., Ltd</institution>
<city>Chengdu</city>
<country country="CN">China</country>
</aff><aff id="prp21186-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">School of Science and Technology</named-content>
<institution>Chengdu Medical College</institution>
<city>Chengdu</city>
<country country="CN">China</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Can Tang, Chengdu Pu Kang Wei Xin Biotechnology Co., Ltd, No. 288 of North section of Rongtai Avenue, Wenjiang District, Chengdu 611130, China.<break/>
Email: <email>tc_tangcan88@126.com</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>21</day><month>3</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2024</year></pub-date><volume>12</volume><issue seq="120">2</issue><issue-id pub-id-type="pmc-issue-id">456532</issue-id><issue-id pub-id-type="doi">10.1002/prp2.v12.2</issue-id><elocation-id>e1186</elocation-id><history><date date-type="rev-recd"><day>18</day><month>2</month><year>2024</year></date><date date-type="received"><day>12</day><month>12</month><year>2023</year></date><date date-type="accepted"><day>26</day><month>2</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>21</day><month>03</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>21</day><month>03</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-03-22 00:25:14.460"><day>22</day><month>03</month><year>2024</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2024 The Authors. <italic toggle="yes">Pharmacology Research &amp; Perspectives</italic> published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley &amp; Sons Ltd.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="PRP2-12-e1186.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:PRP2-12-e1186.pdf"/><abstract><title>Abstract</title><p>We conducted pharmacokinetic research wherein salcaprozate sodium (SNAC) was utilized as a penetration enhancer by incorporating it into pancreatic kininogenase (PK) to improve the bioavailability of pancreatic kininogenase enteric&#8208;coated tablets. We conducted in&#160;vitro studies on PK using the Caco&#8208;2 cell model and quantified PK levels using the enzyme&#8208;linked immunosorbent assay (ELISA) method. We conducted methodological verification by blending SNAC and PK powders into enteric&#8208;coated capsules, and studied the pharmacokinetic characteristics. Based on the PK transport assay, the cumulative permeation rates of the test group that employed a SNAC to PK ratio of 32:1, 16:1, 8:1, 4:1, and 2:1 were 13.574%, 7.597%, 10.653%, 3.755%, and 2.523%, respectively. We conducted a uniformity test on the powder that contained a blend of SNAC and PK. The relative standard deviations (RSDs) for both the power containing SNAC and the power not containing SNAC were less than 10%. Based on the methodological verification, in&#160;vivo pharmacokinetic study of PK met the experimental requirements. As indicated by the results of in&#160;vivo pharmacokinetic research on rats, the test group (This group used SNAC) had a PK AUC<sub>0&#8211;12 h</sub> of 5679.747&#8201;ng/L*h and <italic toggle="no">t</italic>
<sub>1/2</sub> of 4.569&#8201;h, while the control group (This group did not use SNAC) had a PK AUC<sub>0&#8211;12 h</sub> of 4639.665&#8201;ng/L*h and <italic toggle="no">t</italic>
<sub>1/2</sub> of 3.13&#8201;h. This study has established a low&#8208;cost, environmentally friendly, and safe SNAC synthesis route with high process yield suitable for industrial production. SNAC demonstrates an absorption&#8208;enhancing effect on PK, and the optimal ratio of SNAC to PK is determined to be 32:1.</p></abstract><abstract abstract-type="graphical"><p>Research flow chart.<boxed-text position="anchor" content-type="graphic" id="prp21186-blkfxd-0001" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="PRP2-12-e1186-g005.jpg"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="prp21186-kwd-0001">Caco&#8208;2 cells</kwd><kwd id="prp21186-kwd-0002">enhancing absorption</kwd><kwd id="prp21186-kwd-0003">enzyme&#8208;linked immunosorbent assay</kwd><kwd id="prp21186-kwd-0004">pancreatic kininogenase</kwd><kwd id="prp21186-kwd-0005">pharmacokinetics</kwd><kwd id="prp21186-kwd-0006">Salcaprozate sodium</kwd></kwd-group><counts><fig-count count="6"/><table-count count="4"/><page-count count="12"/><word-count count="6393"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>April 2024</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.3.9 mode:remove_FC converted:21.03.2024</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="PRP21186-cit-2001"><string-name name-style="western"><surname>Lv</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Luo</surname><given-names>Q&#8208;D</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>Z&#8208;Y</given-names></string-name>, et al. <article-title>Synthesis of salcaprozate sodium and its significance in enhancing pancreatic kininogenase absorption performance</article-title>. <source>Pharmacol Res Perspect</source>. <year>2024</year>;<volume>12</volume>:<elocation-id>e1186</elocation-id>. doi:<pub-id pub-id-type="doi">10.1002/prp2.1186</pub-id><pub-id pub-id-type="pmid">38511246</pub-id><pub-id pub-id-type="pmcid">PMC10955330</pub-id></mixed-citation>
</p><fn-group id="prp21186-ntgp-0001"><fn fn-type="equal" id="prp21186-note-0001"><p>Zhong Lv and Can Tang these authors contributed equally to this study.</p></fn></fn-group></notes></front><body id="prp21186-body-0001"><def-list list-content="abbreviations" id="prp21186-dl-0001"><title>Abbreviations</title><def-item><term id="prp21186-li-0001">ALP</term><def id="prp21186-li-0002"><p>alkaline phosphatase</p></def></def-item><def-item><term id="prp21186-li-0003">AP</term><def id="prp21186-li-0004"><p>apical</p></def></def-item><def-item><term id="prp21186-li-0005">BL</term><def id="prp21186-li-0006"><p>basolateral</p></def></def-item><def-item><term id="prp21186-li-0007">Caco&#8208;2</term><def id="prp21186-li-0008"><p>Cell the human colon adenocarcinoma cell line</p></def></def-item><def-item><term id="prp21186-li-0009">CDI</term><def id="prp21186-li-0010"><p>carbonyldiimidazole</p></def></def-item><def-item><term id="prp21186-li-0011">DCM</term><def id="prp21186-li-0012"><p>dichloromethane</p></def></def-item><def-item><term id="prp21186-li-0013">DMF</term><def id="prp21186-li-0014"><p>dimethylformamide</p></def></def-item><def-item><term id="prp21186-li-0015">DN</term><def id="prp21186-li-0016"><p>diabetes nephropathy</p></def></def-item><def-item><term id="prp21186-li-0017">EA</term><def id="prp21186-li-0018"><p>ethyl acetate</p></def></def-item><def-item><term id="prp21186-li-0019">Et<sub>3</sub>N</term><def id="prp21186-li-0020"><p>Triethylamine</p></def></def-item><def-item><term id="prp21186-li-0021">GLP&#8208;1</term><def id="prp21186-li-0022"><p>glucagon&#8208;like peptide&#8208;1</p></def></def-item><def-item><term id="prp21186-li-0023">MeOH</term><def id="prp21186-li-0024"><p>methanol</p></def></def-item><def-item><term id="prp21186-li-0025">OD</term><def id="prp21186-li-0026"><p>optical density</p></def></def-item><def-item><term id="prp21186-li-0027">Papp</term><def id="prp21186-li-0028"><p>apparent permeability coefficient</p></def></def-item><def-item><term id="prp21186-li-0029">PE</term><def id="prp21186-li-0030"><p>petroleum ether</p></def></def-item><def-item><term id="prp21186-li-0031">PK</term><def id="prp21186-li-0032"><p>pancreatic kininogenase</p></def></def-item><def-item><term id="prp21186-li-0033">TEER</term><def id="prp21186-li-0034"><p>trans&#8208;epithelial electrical resistance</p></def></def-item><def-item><term id="prp21186-li-0035">THF</term><def id="prp21186-li-0036"><p>tetrahydrofuran</p></def></def-item></def-list><sec id="prp21186-sec-0001"><label>1</label><title>INTRODUCTION</title><p>Diabetic nephropathy (DN) is one of the most common microvascular complications of diabetes mellitus. Its clinical manifestations vary according to the stages of the disease. It is mainly characterized by varying degrees of proteinuria and a decline in kidney function. The incidence of early&#8208;stage diabetic nephropathy is approximately 30%<xref rid="prp21186-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>; hence, necessary interventions during this stage can prevent or delay the progression of DN.<xref rid="prp21186-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> PK has shown significant efficacy in the early treatment of diabetic nephropathy. It demonstrates the capability to eliminate or markedly reduce urinary protein levels, effectively decelerating the progression of diabetic nephropathy and preserving kidney function. However, its primary shortcomings in comparison to other drugs presently available in the market encompass low PK bioavailability and poor patient compliance, necessitating additional research.</p><p>PK belongs to the class of proteolytic enzymes and plays a significantly important role in the human kinin system. Pancreatic kininases can degrade into kinins, which are highly potent vasoactive substance capable of dilating renal blood vessels. They can promote the excretion of water and sodium, lower blood pressure, and increase renal blood flow. Additionally, they reduce pressure in the renal efferent arterioles and capillary resistance, decrease the quantity of protein excreted in urine, and improve kidney function.<xref rid="prp21186-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="prp21186-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="prp21186-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> Presently, the market offers enteric&#8208;coated PK tablets and injectable PK formulations. The bioavailability of enteric&#8208;coated PK tablets remains notably limited, posing a cost escalation concern for pharmaceutical enterprises. This limitation may necessitate consumers to ingest higher individual doses or even undergo multiple administrations for efficacy. Injectable PK, on the other hand, faces issues related to poor patient compliance. The objective of this study was to investigate the absorption&#8208;enhancing effect of the permeability enhancer&#8212;SNAC&#8212;on PK absorption using the Caco&#8208;2 cell absorption model. Subsequently, SNAC&#8208;containing enteric&#8208;coated PK capsules was formulated and studied for their pharmacokinetic characteristics in rat models. We hope our study can enhance the bioavailability of PK, improve drug stability, and provide essential theoretical foundations for the development of novel oral second&#8208;class PK medications.</p></sec><sec sec-type="materials-and-methods" id="prp21186-sec-0002"><label>2</label><title>MATERIALS AND METHODS</title><sec id="prp21186-sec-0003"><label>2.1</label><title>Material</title><sec id="prp21186-sec-0004"><label>2.1.1</label><title>Instruments</title><p>The quality of SNAC was tested using a high&#8208;performance liquid chromatography system (Agilent Technologies [China] Co., Ltd. DEACX12727). Cell morphology was observed using an inverted phase contrast microscope (Nikon Corporation. TA100&#8208;452331). Microplate reader (Molecular Devices Shanghai Co., Ltd. 2016001847), detects the content of PK utilizing a battery resistance meter (Millipore Sigma. ERS&#8208;2&#8208;01) to measure the cell resistance value. The isolation of CaCo&#8208;2 cells was performed by a low&#8208;speed centrifuge (ANHUI USTC Zonkia Scientific Instrument Co., Ltd. 201500013).</p></sec><sec id="prp21186-sec-0005"><label>2.1.2</label><title>Medicines and reagents</title><p>Salicylamide (Huayin Jinqiancheng Pharmaceutical Co., Ltd., Y366220101) is a synthetic raw material for SNAC. PK (Sichuan Deebiotech Co., Ltd. D08&#8208;220501. 90&#8201;U/mg) is the research object.. DMEM medium (Chengdu Yufeng Boyan Biotechnology Co., Ltd.06&#8208;1055&#8208;57&#8208;1ACS) is the culture medium for CaCo&#8208;2 cells. Enhanced CCK&#8208;8 (Beyotime Biotechnology Co., Ltd., Shanghai City. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="C00423">C00423</ext-link>) is used for cytotoxicity experiments. Phosphate&#8208;buffered saline (PBS) solution (Chengdu Yufeng Boyan Biotechnology Co., Ltd. 02&#8211;024&#8208;1ACS.) is the diluent. Film coating powder (Chengdu Taishan Pharmaceutical Co., Ltd. 20221201) is used for PK enteric&#8208;coated capsule coating.</p></sec><sec id="prp21186-sec-0006"><label>2.1.3</label><title>Cell strains</title><p>Caco&#8208;2 human rectal adenocarcinoma cells (Meiwan Biotechnology Co., Ltd., Shanghai City) were used for PK in&#160;vitro study.</p></sec><sec id="prp21186-sec-0007"><label>2.1.4</label><title>Animals</title><p>Eighteen male Sprague&#8211;Dawley (SD) rats weighing 200&#8201;&#177;&#8201;10&#8201;g each were provided by Chengdu Dossy Experimental Animals Co., Ltd. (SCXK 2020&#8208;030).</p></sec></sec><sec id="prp21186-sec-0008"><label>2.2</label><title>The synthesis of <styled-content style="fixed-case" toggle="no">SNAC</styled-content>
</title><sec id="prp21186-sec-0009"><label>2.2.1</label><title>Information of <styled-content style="fixed-case" toggle="no">SNAC</styled-content>
</title><p>SNAC, also known as salcaprozate sodium, has a molecular formula of C<sub>15</sub>H<sub>20</sub>NNaO<sub>4</sub>, a molecular weight of 301.31, and a Chemical Abstracts Service (CAS) registry number of 203787&#8208;91&#8208;1.</p></sec><sec id="prp21186-sec-0010"><label>2.2.2</label><title>The synthesis route of <styled-content style="fixed-case" toggle="no">SNAC</styled-content> is shown in Figure&#160;<xref rid="prp21186-fig-0001" ref-type="fig">1</xref>
</title><fig position="float" fig-type="FIGURE" id="prp21186-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>The synthetic scheme of SNAC.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="PRP2-12-e1186-g006.jpg"/></fig><p>Using salicylamide as the starting raw material, intermediate 1,3&#8208;benzoxazine&#8208;2,4(3H)&#8208;dione was prepared. Subsequently, triethylamine provided alkalinity, and a substitution reaction occurred between 8&#8208;bromooctanoic acid ethyl ester and intermediate 1, yielding intermediate 2. Next, under alkaline conditions, intermediate 2 underwent hydrolysis and ring&#8208;opening reactions, with pH adjustment using hydrochloric acid, resulting in intermediate 8&#8208;(2&#8208;hydroxybenzamido)octanoic acid. Finally, sodium hydroxide provided alkalinity, yielding the desired product, sodium 8&#8208;(2&#8208;hydroxybenzamido)octanoate (commonly known as salcaprozate sodium [SNAC]).</p></sec><sec id="prp21186-sec-0011"><label>2.2.3</label><title>The synthesis of intermediate 1,3&#8208;benzoxazine&#8208;2,4(<styled-content style="fixed-case" toggle="no">3H</styled-content>)&#8208;dione</title><p>Sixty milliliters of THF was measured, put into a round&#8208;bottom flask, stirred, and added with 10&#8201;g of salicylamide and 14.2&#8201;g of carbonyldiimidazole. The mixture was kept overnight at 25&#176;C, monitored by a thin layer chromatography (TLC) plate (PE: EA&#8201;=&#8201;1:1). Upon completion of the reaction, an equal volume of water was added, resulting in solid precipitation. The solid was then filtered, dried, yielding a 93.5% recovery rate.</p></sec><sec id="prp21186-sec-0012"><label>2.2.4</label><title>The synthesis of intermediate 2</title><p>Five grams of the intermediate 1,3&#8208;benzoxazine&#8208;2,4(3H)&#8208;dione were dissolved in a volume of dimethylformamide (DMF) equal to five times its quantity, placed into a round&#8208;bottom flask, slowly stirred, and added with 7.8&#8201;g of triethylamine and 9.2&#8201;g of 8&#8208;bromooctanoic acid ethyl ester. The mixture was reacted at 55&#176;C&#8211;65&#176;C for 6&#8211;10&#8201;h, then cooled to room temperature. Hydrochloric acid at a concentration of 1&#8201;mol/L was added into the reacted mixture to precipitate the solid. Filtration by suction was performed and the filter cake was rinsed with water. Subsequently, the filter cake was pulped twice using a mixture of methyl tert&#8208;butyl ether and n&#8208;heptane in a 5:1 ratio and filtered by suction. Next, the filter cake was rinsed with n&#8208;heptane. The solid was dried at 55&#176;C for approximately 4&#8201;h. The yield was 94.9%.</p></sec><sec id="prp21186-sec-0013"><label>2.2.5</label><title>The synthesis of the intermediate 8&#8208;(2&#8208;hydroxybenzamido)octanoic acid</title><p>A 4.3 g quantity of sodium hydroxide was dissolved in 10 times its weight of water, stirred, and then combined with 8&#8201;g of intermediate 2. The mixture was reacted at 90&#176;C&#8211;100&#176;C for 3&#8211;6&#8201;h, monitored using the TLC plate (DCM: MeOH&#8201;=&#8201;10:1). Upon completion of the reaction, the mixture was subsequently cooled to room temperature, following which impurities were extracted once using dichloromethane (DCM). Verification was performed via TLC analysis. The aqueous phase was then adjusted to a pH range of 3&#8211;5 using 3&#8201;N hydrochloric acid, resulting in the precipitation of solid material. After filtration by suction, the solid was rinsed with water and dried at 60&#176;C for approximately 4&#8201;h, yielding a 94.0% yield.</p></sec><sec id="prp21186-sec-0014"><label>2.2.6</label><title>The synthesis of sodium 8&#8208;(2&#8208;hydroxybenzamido)octanoate (<styled-content style="fixed-case" toggle="no">SNAC</styled-content>)</title><p>The intermediate 8&#8208;(2&#8208;hydroxybenzamido)octanoic acid, weighing 5&#8201;g, was placed into a small amount of isopropanol and stirred, and then a sodium hydroxide solution of 0.7&#8201;g was added dropwise. Subsequently, the remaining isopropanol (totaling 8&#8201;V) was also added. The mixture was slowly cooled with stirring to induce crystallization, and then filtered under suction. The resulting filter cake was rinsed with isopropanol and subsequently dried at 60&#176;C for 2&#8211;4&#8201;h, yielding a 90.8% yield.</p></sec></sec><sec id="prp21186-sec-0015"><label>2.3</label><title>The effect of <styled-content style="fixed-case" toggle="no">SNAC</styled-content> on the intestinal absorption of <styled-content style="fixed-case" toggle="no">PK</styled-content>
</title><p>Caco&#8208;2 cells originate from cell lines of human colonic and rectal cancer.<xref rid="prp21186-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> Their various physiological and tissue morphological characteristics, as well as the secretion of related functional enzymes, are similar to the epithelial cells of the normal human small intestine mucosa. Additionally, they possess similar enzyme systems related to the epithelial cells of the human small intestine mucosa.<xref rid="prp21186-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> Over the past 30&#8201;years of development, as a model for in&#160;vitro cultivation of intestinal mucosal epithelial cells, Caco&#8208;2 cells have been widely used in research on in&#160;vitro drug studies, such as investigations into intestinal absorption, distribution, metabolic functions, and in&#160;vitro excretion functions.<xref rid="prp21186-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="prp21186-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="prp21186-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> Therefore, the Caco&#8208;2 cell model is suitable for studying the cellular absorption and uptake of drugs intended to be absorbed in the intestine, as well as specific transmembrane transport processes.</p><sec id="prp21186-sec-0016"><label>2.3.1</label><title>Cytotoxicity experiment using <styled-content style="fixed-case" toggle="no">CCK</styled-content>&#8208;8</title><p>Logarithmic phase Caco&#8208;2 cells were incubated in 96&#8208;well plates at a concentration of 5&#8201;&#215;&#8201;10<sup>3</sup> cells per well and placed in a 37&#176;C, 5% CO<sub>2</sub> incubator for cultivation. After 24&#8201;h of cultivation, cells were rinsed with PBS. For SNAC cytotoxicity experiment group, 90&#8201;&#956;L of fresh culture medium and 10&#8201;&#956;L of SNAC solution at concentrations of 14, 12, 10, 8, 6, 4, and 2&#8201;mg/mL were added. For the PK cytotoxicity experiment group, 90&#8201;&#956;L of fresh culture medium and 10&#8201;&#956;L of PK solution at concentrations of 18, 16, 12, 10, 8, 6, 4, and 2&#8201;mg/mL were added. Three replicate wells were prepared with corresponding concentrations for the measurement, and the culture lasted for 6 h. After the incubation, the cellular waste liquid was removed by suction, and 90&#8201;&#956;L of fresh culture medium and 10&#8201;&#956;L of CCK8 reagent were added. The mixture was incubated in a 37&#176;C, 5% CO<sub>2</sub> incubator for 1 h. The absorbance was measured using the microplate reader at a wavelength of 450&#8201;nm. The experiment consisted of two groups: a blank control group without cells, and a negative control group with cells but no drug solution. Cell viability was calculated based on the measured absorbance using the following formula:<disp-formula id="prp21186-disp-0001"><label>(1)</label><mml:math id="jats-math-1" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtext>Cell survival rate</mml:mtext><mml:mspace width="0.25em"/><mml:mfenced close=")" open="("><mml:mo>%</mml:mo></mml:mfenced><mml:mo linebreak="goodbreak">=</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="italic">As</mml:mi><mml:mo>&#8722;</mml:mo><mml:mi mathvariant="italic">Ab</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">Ac</mml:mi><mml:mo>&#8722;</mml:mo><mml:mi mathvariant="normal">A</mml:mi><mml:mi>b</mml:mi></mml:mrow></mml:mfrac><mml:mo linebreak="goodbreak">&#215;</mml:mo><mml:mn>100</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula>
</p><p>In this formula, <italic toggle="yes">As</italic> represents the absorbance value of the experimental wells, <italic toggle="yes">Ac</italic> represents the absorbance value of the control wells, and <italic toggle="yes">Ab</italic> represents the absorbance value of the blank wells.</p></sec><sec id="prp21186-sec-0017"><label>2.3.2</label><title>The establishment of the Caco&#8208;2 cell model</title><p>Caco&#8208;2 cells were incubated in the Transwell inserts and placed on a 24&#8208;well plate for culturation and growth. The AP inner surface of the Transwell inserts contained approximately 0.5&#8201;mL of culture medium, while the BL side contained approximately 1.5&#8201;mL of culture medium. The cells were then cultured for 21&#8201;days. The Caco&#8208;2 cell model followed the model established by Lv Xiaojun et&#160;al.<xref rid="prp21186-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>
</p></sec><sec id="prp21186-sec-0018"><label>2.3.3</label><title>Measurement of Caco&#8208;2 Cell monolayer <styled-content style="fixed-case" toggle="no">TEER</styled-content>
</title><p>First, the Millicell&#8208;ERS electrical resistance meter was used to calibrate the resistance and voltage. Initial measurements involved the blank Transwell wells without Caco&#8208;2 cells, followed by determining the transmembrane resistance values of the Transwell wells with cultured Caco&#8208;2 cells. The actual resistance value of the Caco&#8208;2 cell monolayer was calculated using the following formula.<disp-formula id="prp21186-disp-0002"><label>(2)</label><mml:math id="jats-math-2" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtext>TEER</mml:mtext><mml:mo linebreak="goodbreak">=</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mi>R</mml:mi><mml:mo linebreak="goodbreak">&#8722;</mml:mo><mml:mi mathvariant="italic">Rb</mml:mi></mml:mrow></mml:mfenced><mml:mo linebreak="goodbreak">&#215;</mml:mo><mml:mi>A</mml:mi><mml:mspace width="0.25em"/><mml:mfenced close=")" open="("><mml:mrow><mml:mi mathvariant="normal">&#937;</mml:mi><mml:mo>&#183;</mml:mo><mml:msup><mml:mi>cm</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math></disp-formula>
</p><p>Among them, <italic toggle="yes">R</italic> represents the actual resistance value, <italic toggle="yes">Rb</italic> is the value of the blank Transwell wells, and <italic toggle="yes">A</italic> is the membrane area of the polycarbonate film (0.33&#8201;cm<sup>2</sup>).</p><p>The resistance values were measured on the 2nd, 5th, 7th, 10th, 15th, 21st, and 22nd days after seeding Caco&#8208;2 cells into Transwell inserts.</p></sec><sec id="prp21186-sec-0019"><label>2.3.4</label><title>Determination of <styled-content style="fixed-case" toggle="no">ALP</styled-content> activity</title><p>On the 4th, 7th, 14th, and 21st days of the cultivation stage, culture medium from the AP and BL surfaces of the cells was respectively collected and transferred into 1.5&#8201;mL EP tubes to create cell samples. The ALP activity was then determined following the steps outlined in the ALP bioactivity rapid detection kit (P0321M).</p></sec><sec id="prp21186-sec-0020"><label>2.3.5</label><title>Permeability determination of Caco&#8208;2 cell monolayer model</title><p>Phenol red is a water&#8208;soluble substance with a relatively large molecular weight. Therefore, its transport through cell channels is challenging. It can be used as a marker to detect the permeation quantity of substances in the cell monolayer model, indirectly assessing the structural integrity of the cell monolayer model. Papp value reflects the ability of substances to pass through the monolayer cell barrier and the extent of their absorption.<xref rid="prp21186-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> Therefore, experimental evaluators used phenol red solely as a marker in this identification process.</p></sec><sec id="prp21186-sec-0021"><label>2.3.6</label><title>Transwell drug transport experiment</title><p>PK levels were determined using double&#8208;antibody sandwich ELISA, during which the ELISA kit instructions were referred.</p><p>The concentration of the standard sample (&#956;g/mL) was used as the <italic toggle="yes">x</italic>&#8208;axis and the corresponding optical density (OD) values as the <italic toggle="yes">y</italic>&#8208;axis. A linear regression curve was established based on the standard sample. The sample concentration was then calculated based on this curve, allowing for the subsequent calculation of the cumulative permeation <italic toggle="yes">Q</italic> per unit area. The formula is as follows:<disp-formula id="prp21186-disp-0003"><label>(3)</label><mml:math id="jats-math-3" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>Q</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:msub><mml:mo linebreak="goodbreak">=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>VC</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:munderover><mml:mo>&#8721;</mml:mo><mml:mrow><mml:mi mathvariant="normal">i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="normal">n</mml:mi><mml:mo>&#8722;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:munderover><mml:msub><mml:mi>C</mml:mi><mml:mi mathvariant="normal">i</mml:mi></mml:msub><mml:msub><mml:mi>V</mml:mi><mml:mi mathvariant="normal">i</mml:mi></mml:msub></mml:mrow><mml:mi>A</mml:mi></mml:mfrac></mml:mrow></mml:mrow></mml:math></disp-formula>
</p><p>Among them, <italic toggle="yes">A</italic> represents the transport membrane area (0.33&#8201;cm <sup>2</sup>), <italic toggle="yes">V</italic> denotes the volume of the Transwell inserts on the BL side, <italic toggle="yes">C</italic>
<sub>n</sub> signifies the drug concentration on the BL side during the n<sup>th</sup> sampling, <italic toggle="yes">C</italic>
<sub>i</sub> represents the drug concentration on the BL side during the i<sup>th</sup> sampling, and <italic toggle="yes">V</italic>
<sub>i</sub> stands for the volume during the i<sup>th</sup> sampling.</p><sec id="prp21186-sec-0022"><title>Solution preparation</title><p>Ten milligrams of SNAC and 10 mg of PK were precisely weighed and diluted using PBS solution to achieve the desired concentration. The concentration of SNAC was 1000&#8201;&#956;g/mL. The test group used SNAC with concentrations of SNAC and PK at ratios of 32:1, 16:1, 8:1, 4:1, and 2:1, respectively. while the control group did not contain SNAC.</p><p>After successfully establishing the Caco&#8208;2 cell monolayer transport model, the culture medium from the upper and lower portions of the Transwell inserts was gently suctioned and removed. Subsequently, the upper and lower portions of the Transwell inserts were rinsed twice with preheated PBS solution at 37&#176;C. Following rinsing, 350&#8201;&#956;L of PBS solution was added to the AP side, while 1&#8201;mL of PBS was added to the BL side. The Transwell inserts were then incubated for 30&#8201;min in a cell culture incubator. Following incubation, the PBS solution from the AP and BL sides of the inserts were discarded. For both the test and control groups, 350&#8201;&#956;L of the sample solution was added to the AP side of the Transwell inserts, while 1&#8201;mL of PBS solution was added to the BL side. For the blank group, a corresponding volume of PBS solution was added to both the AP and BL sides. Subsequently, the inserts were returned to the cell culture incubator, and samples were collected at 30, 60, 90, and 120&#8201;min. Each sampling instance involved withdrawing 200&#8201;&#956;L of the mixed solution and replacing it with an equal volume of PBS. At 120&#8208;min sampling, both the upper and lower portions of the Transwell inserts were fully collected, then transferred to centrifuge tubes, and stored in a &#8722;20&#176;C freezer for subsequent processing.</p></sec><sec id="prp21186-sec-0023"><title>PK standard curve</title><p>Linear regression was performed using PK concentration (<italic toggle="yes">x</italic>) and OD values (<italic toggle="yes">y</italic>) to plot the standard curve.</p></sec><sec id="prp21186-sec-0024"><title>Transport experiment</title><p>Using a PK drug solution without SNAC as a control, drug transport experiments were conducted using a PK drug solution containing SNAC in the Caco&#8208;2 cell model for 2 h. Samples were collected at 30, 60, 90, and 120&#8201;min, followed by the use of an ELISA assay kit to detect and measure the PK concentration in the samples. The cumulative permeation quantity (Q) and the cumulative permeation rate (%) per unit area were calculated.</p></sec></sec></sec><sec id="prp21186-sec-0025"><label>2.4</label><title>Pharmacokinetic study of <styled-content style="fixed-case" toggle="no">PK</styled-content> enteric&#8208;coated capsules</title><sec id="prp21186-sec-0026"><label>2.4.1</label><title>Processing of plasma samples</title><p>The experimental animals were divided into blank group, control group, and experimental group, with six rats in each group, and all of them were given a PK enteric&#8208;coated capsule with a titer of 15&#8201;U.</p><p>Blood from the rat's retro&#8208;orbital venous plexus at 0.3&#8201;mL was collected using a 0.5&#8201;mm capillary tube and transferred into a centrifuge tube that had been infiltrated and rinsed using 0.6&#8201;mL heparin sodium injection solution and dried. After being placed for 20&#8201;min, the blood sample underwent centrifugation at 1500&#8201;g for 20&#8201;min. Following centrifugation, a pipette was utilized to extract the supernatant, and the resulting plasma was stored in a freezer set at &#8722;20&#176;C for subsequent use.</p></sec><sec id="prp21186-sec-0027"><label>2.4.2</label><title>Preparation and assessment of <styled-content style="fixed-case" toggle="no">PK</styled-content> enteric&#8208;coated capsules</title><p>According to the recommended daily dosage of PK enteric&#8208;coated tablets for adults, the equivalent dosage for rat administration is 15&#8201;U/each, signifying that each enteric&#8208;coated capsule contains 0.17&#8201;mg of PK.</p><p>The control group without SNAC: 9.83&#8201;g of starch were precisely weighed and placed in an agate mortar. Meticulously weighed PK, totaling 0.17&#8201;g, was added to the starch. The mixture was ground slowly for 1.5&#8201;h. After confirming the uniformity of the mixture, it was filled into empty capsules and then subjected to enteric coating.</p><p>The test group with SNAC (SNAC&#1475; PK&#8201;=&#8201;32:1): 4.39&#8201;g of starch were precisely weighed and placed in an agate mortar. Subsequently, 5.44&#8201;g of SNAC were added to the agate mortar, followed by the precise addition of 0.17&#8201;g of PK. The components were thoroughly mixed together and ground slowly until achieving uniformity. Upon confirming the uniformity of the mixture, it was filled into empty capsules and then underwent an enteric coating process.</p><p>The upper, lower, left, right, and middle portions of the mixed powder were gathered and recombined. It was deemed to meet the standard if the RSD was less than 10%.</p></sec><sec id="prp21186-sec-0028"><label>2.4.3</label><title>Determination of <styled-content style="fixed-case" toggle="no">PK</styled-content> concentration in plasma using the <styled-content style="fixed-case" toggle="no">ELISA</styled-content> method</title><p>The ELISA kit instruction manual was referred.</p></sec><sec id="prp21186-sec-0029"><label>2.4.4</label><title>Methodological evaluation</title><sec id="prp21186-sec-0030"><title>Preparation of standard solution</title><p>Ten milligrams of PK were accurately weighed, placed in a 10&#8201;mL volumetric flask, dissolved in PBS solution, made up to the mark, and prepared into a standard solution with a concentration of 1&#8201;mg/mL.</p></sec><sec id="prp21186-sec-0031"><title>Assessment of specificity</title><p>The PK standard solution with a concentration of 1&#8201;mg/mL was diluted by a specific factor to produce standard solutions used for preparing plasma at concentrations of 1200, 600, 300, 150, and 75&#8201;ng/L. The PK standard solution, with a concentration of 1&#8201;mg/mL, was diluted using blank rat plasma to create plasma samples that contained standard solutions and had concentrations of 1200, 600, 300, 150, and 75&#8201;ng/L. The OD values of the PK standard solution, plasma samples containing standard solutions, and blank plasma were measured using the ELISA method.</p></sec><sec id="prp21186-sec-0032"><title>Investigation of linearity range</title><p>Plasma samples that contained standard solutions and had concentrations of 1200, 600, 300, 150, and 75&#8201;ng/L were prepared. The OD values of PK were measured using the ELISA method. Linear fitting was performed using PK mass concentration as the y&#8208;axis and OD values as the <italic toggle="yes">x</italic>&#8208;axis. The linearity within the range of 75&#8211;1200&#8201;ng/L met the experimental requirements.</p></sec><sec id="prp21186-sec-0033"><title>Investigation of recovery rate</title><p>Plasma samples that contained standard solutions and had concentrations of 1000, 500, and 100&#8201;ng/L were prepared. Three replicates for each concentration were prepared. The OD values of PK were measured using the ELISA method. The recovery rate was measured as the measured value/added amount &#215;&#8201;100%. An RSD &lt;5% indicated good accuracy for this detection method.</p></sec><sec id="prp21186-sec-0034"><title>Precision test</title><p>Plasma samples that contained standard solutions and had concentrations of 1000, 500, and 100&#8201;ng/L were prepared. Three replicates for each concentration were prepared. The OD values of PK were measured using the ELISA method for three consecutive days. Within&#8208;batch and inter&#8208;batch precision were assessed. An RSD of &lt;10% was considered indicative of good precision.</p></sec><sec id="prp21186-sec-0035"><title>Assessment of stability</title><p>Plasma samples that contained standard solutions and had concentrations of 1200, 600, and 150&#8201;ng/L were prepared. Three replicates for each concentration were prepared. The plasma samples were store at &#8722;20&#176;C, and slowly thawed in a refrigerator at 4&#176;C. The OD values of PK on the first, third, and seventh days were measured using the ELISA method. An RSD of &lt;10% was considered indicative of good stability.</p></sec></sec><sec id="prp21186-sec-0036"><label>2.4.5</label><title>Pharmacokinetic experiments</title><p>Rats were selected as experimental animals. The rats were divided into three groups: the blank control group, the group receiving SNAC&#8208;containing PK enteric&#8208;coated capsules, and the group receiving PK enteric&#8208;coated capsules without SNAC, with six rats in each group. The rats fasted but were not water&#8208;deprived 24&#8201;h before the experiment, as well as during the experiment. The three groups were orally administered. At 0.25, 0.5, 1, 2, 4, 6, 8, 10, and 12&#8201;h after administration, 0.3&#8201;mL of blood was collected from the rat retro&#8208;orbital venous plexus using a 0.5&#8201;mm capillary tube. The collected blood was stored in a 0.6&#8201;mL EP tube that had been infiltrated with sodium heparin injection solution, and gently rocked up and down to prevent coagulation. The blood plasma was separated according to the method under section &#8220;2.4.1,&#8221; and stored at &#8722;20&#176;C. The OD value of PK was determined using the ELISA method and substituted into the regression equation to obtain PK concentration in blood. Drug concentration&#8211;time curves were drawn using DAS 3.0 software.</p></sec></sec><sec id="prp21186-sec-0037"><label>2.5</label><title>Statistical methods</title><p>Statistical analysis, data processing, and computer&#8208;generated plots were conducted using statistical analysis software such as Microsoft Excel 2010 and SPSS Statistics 21. The statistical analysis method&#8212;mean&#8201;&#177;&#8201;standard deviation (<mml:math id="jats-math-4" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mi>x</mml:mi><mml:mo>&#175;</mml:mo></mml:mover><mml:mo>&#177;</mml:mo><mml:mi mathvariant="italic">SD</mml:mi></mml:mrow></mml:mrow></mml:math>)&#8212;was directly employed to model and describe the differential data results statistically. Various differential data results obtained from single&#8208;factor statistical analyses were synthesized and compared. Microsoft Excel 2010 was utilized for linear fitting to derive regression equations and plot standard curves. The software DAS 3.0 was used for pharmacokinetic analysis.</p></sec></sec><sec sec-type="results" id="prp21186-sec-0038"><label>3</label><title>RESULTS</title><sec id="prp21186-sec-0039"><label>3.1</label><title>Comparison of the quality standards of synthesized <styled-content style="fixed-case" toggle="no">SNAC</styled-content>
</title><p>As depicted in Table&#160;<xref rid="prp21186-tbl-0001" ref-type="table">1</xref>, all the properties and components of the synthesized SNAC met the respective quality standards, including characteristics, relevant substances, high&#8208;resolution nuclear magnetic resonance (HNMR), moisture, and other parameters. Particle size distribution and crystallographic data are shown in Figure&#160;<xref rid="prp21186-fig-0002" ref-type="fig">2</xref>.</p><table-wrap position="float" id="prp21186-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Comparison of quality standards.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Item</th><th align="left" valign="bottom" rowspan="1" colspan="1">Standard</th><th align="left" valign="bottom" rowspan="1" colspan="1">Synthesized SNAC</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Characteristics</td><td align="left" valign="top" rowspan="1" colspan="1">Off&#8208;white to pink powder</td><td align="left" valign="top" rowspan="1" colspan="1">Off&#8208;white powder</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">Relevant substance</td><td align="left" valign="top" rowspan="1" colspan="1">Main peak &#8805;98.5%</td><td align="left" valign="top" rowspan="1" colspan="1">Main peak&#8201;=&#8201;99.9%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Maximum individual impurity &lt;0.1%</td><td align="left" valign="top" rowspan="1" colspan="1">Maximum individual impurity&#8201;=&#8201;0.02%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HNMR</td><td align="left" valign="top" rowspan="1" colspan="1">No apparent impurities</td><td align="left" valign="top" rowspan="1" colspan="1">Conforming</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Moisture</td><td align="left" valign="top" rowspan="1" colspan="1">Less than 0.2%</td><td align="left" valign="top" rowspan="1" colspan="1">0.06%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Heavy metals</td><td align="left" valign="top" rowspan="1" colspan="1">Not exceeding 20/1&#8201;000&#8201;000</td><td align="left" valign="top" rowspan="1" colspan="1">Conforming</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">Residual solvents</td><td align="left" valign="top" rowspan="1" colspan="1">Methanol &#8804;0.3%</td><td align="left" valign="top" rowspan="1" colspan="1">Methanol&#8201;=&#8201;0.01%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Isopropanol &#8804;1.0%</td><td align="left" valign="top" rowspan="1" colspan="1">Isopropanol&#8201;=&#8201;0.48%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Particle size</td><td align="left" valign="top" rowspan="1" colspan="1">D50&#8201;=&#8201;10&#8201;~&#8201;23&#8201;&#956;m</td><td align="left" valign="top" rowspan="1" colspan="1">D50&#8201;=&#8201;21.57&#8201;&#956;m</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">XRD</td><td align="left" valign="top" rowspan="1" colspan="1">In conformity with noncrystalline Type I</td><td align="left" valign="top" rowspan="1" colspan="1">Conforming</td></tr></tbody></table></table-wrap><fig position="float" fig-type="FIGURE" id="prp21186-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Granticle distribution plot (A) and crystalline form data (B) of SNAC.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="PRP2-12-e1186-g004.jpg"/></fig></sec><sec id="prp21186-sec-0040"><label>3.2</label><title>
<styled-content style="fixed-case" toggle="no">SNAC</styled-content> promotes intestinal absorption of <styled-content style="fixed-case" toggle="no">PK</styled-content>
</title><sec id="prp21186-sec-0041"><label>3.2.1</label><title>Results of cytotoxicity experiments</title><p>As indicated by the test results, when the concentration of SNAC reached 1000&#8201;&#956;g/mL, the survival rate of Caco&#8208;2 cells was higher than 95%. Therefore, within the range of 0&#8211;1000&#8201;&#956;g/mL, the toxicity of SNAC to Caco&#8208;2 cells within 6&#8201;h is very weak and can be considered negligible. When the concentration of PK reached 1200&#8201;&#956;g/mL, the survival rate of Caco&#8208;2 cells was higher than 100%. Consequently, within the range of 0&#8211;1200&#8201;&#956;g/mL, PK exhibits no toxicity within 6&#8201;h.</p></sec><sec id="prp21186-sec-0042"><label>3.2.2</label><title>Caco&#8208;2 cell model</title><p>Caco&#8208;2 cell morphology on Transwell culture dishes was observed using an inverted microscope and the results are displayed in Figure&#160;<xref rid="prp21186-fig-0003" ref-type="fig">3</xref>. The cell growth rate was relatively uniform with very distinct boundaries. Good intercellular connections were present. As the cells continued to proliferate, covering the walls of the culture dish, they exhibited a cobblestone&#8208;like appearance, which can be utilized for subsequent experiments.</p><fig position="float" fig-type="FIGURE" id="prp21186-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Morphological structure diagram of Caco&#8208;2 cells. (A)&#160;Day 1 (B) Day 10, and (C) Day 21.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="PRP2-12-e1186-g001.jpg"/></fig></sec><sec id="prp21186-sec-0043"><label>3.2.3</label><title>Caco&#8208;2 cell monolayer <styled-content style="fixed-case" toggle="no">TEER</styled-content>
</title><p>With the increase in days of cell culture, TEER gradually increased. By the 21st day, TEER reached 976.5&#8201;&#937;*cm<sup>2</sup>. Moreover, the resistance remained stable before and after the transport experiment, demonstrating that the Caco&#8208;2 cell monolayer model constructed in this experiment was tight and exhibited a good level of cell integrity.</p></sec><sec id="prp21186-sec-0044"><label>3.2.4</label><title>The <styled-content style="fixed-case" toggle="no">ALP</styled-content> activity</title><p>With increases in cell culture duration, a notable increase in the ratio of ALP activity was observed between the cells on the AP side and those on the BL side. This result demonstrates the expression of APK on the AP side and consequently confirms the occurrence of polarization. A ratio of AP to BP greater than 3 indicates the completion of polarization and differentiation of Caco&#8208;2 cells. (Table&#160;<xref rid="prp21186-tbl-0002" ref-type="table">2</xref>).</p><table-wrap position="float" id="prp21186-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Relationship of ALP activity on the AP and BL sides of the monolayer of Caco&#8208;2 cells to culture time (<mml:math id="jats-math-5" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mi>x</mml:mi><mml:mo stretchy="true">&#175;</mml:mo></mml:mover><mml:mo>&#177;</mml:mo><mml:mi mathvariant="italic">SD</mml:mi></mml:mrow></mml:mrow></mml:math>, <italic toggle="no">n</italic>&#8201;=&#8201;3).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Time (days)</th><th align="left" valign="bottom" rowspan="1" colspan="1">AP</th><th align="left" valign="bottom" rowspan="1" colspan="1">BP</th><th align="left" valign="bottom" rowspan="1" colspan="1">AP/BP</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">2.938&#8201;&#177;&#8201;0.129</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">2.078&#8201;&#177;&#8201;0.185</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">1.425&#8201;&#177;&#8201;0.198</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">7</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">6.984&#8201;&#177;&#8201;0.442</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">3.693&#8201;&#177;&#8201;0.553</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">1.911&#8201;&#177;&#8201;0.228</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">14</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">8.073&#8201;&#177;&#8201;0.485</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">2.119&#8201;&#177;&#8201;0.184</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">3.816&#8201;&#177;&#8201;0.122</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">21</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">11.460&#8201;&#177;&#8201;2.189</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">1.813&#8201;&#177;&#8201;0.284</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">6.305&#8201;&#177;&#8201;0.381</td></tr></tbody></table></table-wrap></sec><sec id="prp21186-sec-0045"><label>3.2.5</label><title>Permeability of the Caco&#8208;2 cell monolayer model</title><p>The permeation was determined at day 21 of the experiment, which was a more accurate determination that confirmed the integrity of the Caco&#8208;2 cell model, as depicted in Table&#160;<xref rid="prp21186-tbl-0003" ref-type="table">3</xref>.</p><table-wrap position="float" id="prp21186-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 3</label><caption><p>Results of permeation using phenol red (<mml:math id="jats-math-6" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mi>x</mml:mi><mml:mo stretchy="true">&#175;</mml:mo></mml:mover><mml:mo>&#177;</mml:mo><mml:mi mathvariant="italic">SD</mml:mi></mml:mrow></mml:mrow></mml:math>, <italic toggle="no">n</italic>&#8201;=&#8201;3).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Items</th><th align="left" valign="bottom" rowspan="1" colspan="1">Results</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Regression equation</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">y</italic>&#8201;=&#8201;0.0084<italic toggle="yes">x</italic>&#8201;+&#8201;0.0512</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Correlation coefficient (<italic toggle="yes">r</italic>)</td><td align="left" valign="top" rowspan="1" colspan="1">0.9996</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Papp(cm/s)</td><td align="left" valign="top" rowspan="1" colspan="1">7.06&#8201;&#215;&#8201;10<sup>&#8722;8</sup>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Reference value</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;1&#8201;&#215;&#8201;10<sup>&#8722;6</sup>
</td></tr></tbody></table></table-wrap></sec><sec id="prp21186-sec-0046"><label>3.2.6</label><title>Results of Transwell drug transport experiment</title><p>PK standard curve: A linear regression was performed using PK concentration (<italic toggle="yes">x</italic>&#8208;axis) and OD value (<italic toggle="yes">y</italic>&#8208;axis). The equation of the standard curve is <italic toggle="yes">y</italic>&#8201;=&#8201;0.0208<italic toggle="yes">x</italic>&#8201;+&#8201;0.168 (<italic toggle="yes">r</italic>&#8201;=&#8201;0.9995). A concentration range of 7.5&#8211;120&#8201;ng/mL showed good linearity.</p><p>Based on the transport results, the test groups that used a SNAC to PK ratio of 32:1, 16:1, 8:1, 4:1, and 2:1 experienced a significantly higher cumulative PK permeation quantity than the control group without SNAC, with the cumulative PK permeation quantity increasing by 14.50%, 9.50%, 26.8%, 5.27%, and 3.9%, respectively. SNAC demonstrated an enhancing effect on the transport of PK, and the most effective ratio was SNAC:PK&#8201;=&#8201;8:1. This result is similar to the findings in the research of Buckley S T<xref rid="prp21186-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> et&#160;al. studying the interaction between SNAC and GLP&#8208;1 drugs. However, the permeation rate was low. The highest cumulative permeation rate was observed at SNAC:PK&#8201;=&#8201;1:1 (Figure&#160;<xref rid="prp21186-fig-0004" ref-type="fig">4</xref>).</p><fig position="float" fig-type="FIGURE" id="prp21186-fig-0004" orientation="portrait"><label>FIGURE 4</label><caption><p>Concentration of PK (A) and cumulative permeation (B) at different time points (SNAC:PK&#8201;=&#8201;32:1) (<mml:math id="jats-math-7" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mi>x</mml:mi><mml:mo stretchy="true">&#175;</mml:mo></mml:mover><mml:mo>&#177;</mml:mo><mml:mi mathvariant="italic">SD</mml:mi></mml:mrow></mml:mrow></mml:math>, <italic toggle="yes">n</italic>&#8201;=&#8201;3). *<italic toggle="yes">P</italic>&lt;0.05 when compared with the group that did not use SNAC at 30&#8201;min.** <italic toggle="yes">P</italic>&lt;0.01 when compared with the group that did not use SNAC at 30&#8201;min. *<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05, **<italic toggle="yes">P</italic>&lt;0.01.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-9" orientation="portrait" xlink:href="PRP2-12-e1186-g002.jpg"/></fig></sec></sec><sec id="prp21186-sec-0047"><label>3.3</label><title>Pharmacokinetics of <styled-content style="fixed-case" toggle="no">PK</styled-content> enteric&#8208;coated capsules</title><sec id="prp21186-sec-0048"><label>3.3.1</label><title>Evaluation of the preparation results of <styled-content style="fixed-case" toggle="no">PK</styled-content> enteric&#8208;coated capsules</title><p>PK potency averages, with no SANC and SNAC at a ratio of 32:1, were 1.58 and 0.87&#8201;U/mg, respectively. The RSDs were 5.31% and 3.04%, respectively, both less than 10%, meeting the requirements.</p></sec><sec id="prp21186-sec-0049"><label>3.3.2</label><title>Methodological evaluation</title><sec id="prp21186-sec-0050"><title>Assessment of specificity</title><p>The results indicated that the OD values of the PK standard solution were similar to the plasma containing standard solutions. The OD values of the blank plasma were similar to those of the control blank wells, suggesting that neither the blank plasma nor the blank wells interfered with the PK determination. The results are displayed in Table&#160;<xref rid="prp21186-tbl-0004" ref-type="table">4</xref>.</p><table-wrap position="float" id="prp21186-tbl-0004" content-type="TABLE" orientation="portrait"><label>TABLE 4</label><caption><p>Detection results of various solutions using ELISA (OD value).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">PK mass concentration (ng/L)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Standard solution</th><th align="left" valign="bottom" rowspan="1" colspan="1">Plasma containing standard solutions</th><th align="left" valign="bottom" rowspan="1" colspan="1">Blank plasma</th><th align="left" valign="bottom" rowspan="1" colspan="1">Blank wells</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">1200</td><td align="left" valign="top" rowspan="1" colspan="1">1.764</td><td align="left" valign="top" rowspan="1" colspan="1">1.516</td><td align="left" valign="top" rowspan="1" colspan="1">0.041</td><td align="left" valign="top" rowspan="1" colspan="1">0.041</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">600</td><td align="left" valign="top" rowspan="1" colspan="1">0.798</td><td align="left" valign="top" rowspan="1" colspan="1">0.713</td><td align="left" valign="top" rowspan="1" colspan="1">0.040</td><td align="left" valign="top" rowspan="1" colspan="1">0.040</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">300</td><td align="left" valign="top" rowspan="1" colspan="1">0.427</td><td align="left" valign="top" rowspan="1" colspan="1">0.309</td><td align="left" valign="top" rowspan="1" colspan="1">0.041</td><td align="left" valign="top" rowspan="1" colspan="1">0.039</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">150</td><td align="left" valign="top" rowspan="1" colspan="1">0.231</td><td align="left" valign="top" rowspan="1" colspan="1">0.207</td><td align="left" valign="top" rowspan="1" colspan="1">0.042</td><td align="left" valign="top" rowspan="1" colspan="1">0.042</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">75</td><td align="left" valign="top" rowspan="1" colspan="1">0.120</td><td align="left" valign="top" rowspan="1" colspan="1">0.101</td><td align="left" valign="top" rowspan="1" colspan="1">0.041</td><td align="left" valign="top" rowspan="1" colspan="1">0.041</td></tr></tbody></table></table-wrap></sec><sec id="prp21186-sec-0051"><title>Assessment of linearity</title><p>Linear regression was performed using PK mass concentration as the <italic toggle="yes">y</italic>&#8208;axis and OD values as the <italic toggle="yes">x</italic>&#8208;axis to obtain the regression equation&#8212;<italic toggle="yes">y</italic>&#8201;=&#8201;790.53<italic toggle="yes">x</italic>&#8201;+&#8201;14.712 (<italic toggle="yes">r</italic>&#8201;=&#8201;0.9978). The results indicated that the linear range of mass concentration for PK detection was 75&#8211;1200&#8201;ng/L, meeting the experimental requirements.</p></sec><sec id="prp21186-sec-0052"><title>Assessment of recovery rate</title><p>As shown by the test results, the RSD of plasma samples that contained standard solutions and had concentrations of 1000, 500, and 100&#8201;ng/L were 0.561%, 0.813%, and 2.354%, respectively (<italic toggle="yes">n</italic>&#8201;=&#8201;3). All of them were less than 5%, meeting the experimental requirements.</p></sec><sec id="prp21186-sec-0152"><title>Precision test</title><p>As demonstrated by the test results, the within&#8208;batch RSD of plasma samples that contained standard solutions and had concentrations of 1000, 500, and 100&#8201;ng/L were 5.01%, 3.04%, and 3.77%, respectively (<italic toggle="yes">n</italic>&#8201;=&#8201;3), while those of the inter&#8208;batch RSD were 4.39%, 3.47%, and 4.19%, respectively (<italic toggle="yes">n</italic>&#8201;=&#8201;9). All RSDs were less than 10%, meeting the experimental requirements.</p></sec><sec id="prp21186-sec-0053"><title>Assessment of stability</title><p>As indicated by the results, the RSDs of OD values of plasma samples that contained standard solutions and had concentrations of 1200, 600, and 150&#8201;ng/L were 3.14%, 7.36%, 8.24%, respectively (<italic toggle="yes">n</italic>&#8201;=&#8201;9). All of them were less than 10%, proving good stability of PK under these conditions.</p></sec></sec><sec id="prp21186-sec-0054"><label>3.3.3</label><title>Pharmacokinetics</title><p>As shown by the test results (Figure&#160;<xref rid="prp21186-fig-0005" ref-type="fig">5</xref>), in the rats' bodies, the PK in the PK enteric&#8208;coated capsules that contained SANC had a pharmacokinetic AUC<sub>0&#8208;12 h</sub> of 5679.747&#8201;ng/L*h and a pharmacokinetic <italic toggle="yes">t</italic>
<sub>1/2</sub> of 4.569&#8201;h, while the PK in the PK enteric&#8208;coated capsules that did not contain SANC had a pharmacokinetic AUC<sub>0&#8211;12 h</sub> of 4639.665&#8201;ng/L*h and a pharmacokinetic <italic toggle="yes">t</italic>
<sub>1/2</sub> of 3.13&#8201;h. This indicates that the addition of SANC increased the AUC by 22%. Moreover, the <italic toggle="yes">C</italic>
<sub>max</sub> in the group using PK enteric&#8208;coated capsules that contained SANC was higher than in the&#160;group using PK enteric&#8208;coated capsules that did not contain SANC. This indicated that the inclusion of SANC, a permeation enhancer, allows more active ingredients to reach the site of action, thereby exerting efficacy. This suggests that the use of SANC can increase the PK concentration in the rat blood, offering advantages over formulations lacking SANC. This lays the groundwork for the future development of PK as a new type of orally administered second&#8208;class drug.</p><fig position="float" fig-type="FIGURE" id="prp21186-fig-0005" orientation="portrait"><label>FIGURE 5</label><caption><p>The PK concentration&#8211;time curve of rat blood in&#160;vivo.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-11" orientation="portrait" xlink:href="PRP2-12-e1186-g003.jpg"/></fig></sec></sec></sec><sec sec-type="discussion" id="prp21186-sec-0055"><label>4</label><title>DISCUSSION</title><p>ELISA is a type of microanalysis technique that combines the amplifying effect of enzyme catalysis with the specific antigen&#8211;antibody reaction. It is a commonly employed method that integrates high&#8208;throughput screening with quantitative detection, suitable for analyzing large batches of samples. Its applications are widespread, encompassing fields such as immunological experimental analysis, medical diagnostics, and food safety.<xref rid="prp21186-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> The principle of ELISA relies on the specific interaction between antigens and antibodies, utilizing enzyme labeling and chromogenic reactions. It utilizes immune methods for both qualitative and quantitative determinations, demonstrating high sensitivity capable of detecting levels as high as nanograms (ng) or even picograms (pg). Its advantages include strong specificity, high accuracy, straightforward operation, and safety.<xref rid="prp21186-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="prp21186-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="prp21186-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> However, ELISA requires strict control of time and temperature, which can lead to poor reproducibility and susceptibility to interference from endogenous antibodies and enzymes. Therefore, in this study, methodological investigations were conducted regarding the linear range, recovery rate, accuracy, and precision of ELISA quantitative measurements, all of which met the standard requirements.</p><p>The absorption enhancer selected in this study was SNAC, primarily used to overcome the absorption barriers of drugs and enhance the bioavailability of specific orally administered protein and peptide (or polypeptide) drugs. SNAC, as an amino acid derivative, can increase the oral absorption of various protein drugs such as heparin and human growth hormone without relying on drug formula protection. Moreover, it does not have a short&#8208;term impact on the vitality of gastrointestinal cells.<xref rid="prp21186-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="prp21186-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> This research on SNAC is mainly limited to protein drugs, with most studies investigating its absorption&#8208;enhancing effects in the stomach. This study focused on the effect of SNAC on enhancing the absorption of PK, providing a theoretical basis for its role in promoting drug absorption in the intestine and investigating the impact of SNAC on the vitality of intestinal cells. SNAC possesses enormous potential for future applications. As a broad&#8208;spectrum absorption enhancer, it can be used not only to promote drug absorption and develop new types of drugs but also holds potential applications in other areas.</p><p>The most important aspect of the research on the Caco&#8208;2 cell absorption model is the establishment of a monolayer membrane. Therefore, evaluating the integrity and tightness of the membrane is crucial. There are various evaluation methods. Besides the ALP method and the phenol red method mentioned in this article, there are other evaluation methods such as cell resistance determination, mannitol permeation, electron microscopy for ultrastructure observation, etc. Overall, during the modeling process, two or more methods are needed, with the goal of reducing errors and providing a more comprehensive assessment of the monolayer membrane's tightness and integrity. The Caco&#8208;2 cell absorption model method holds substantial potential applications, progressively assuming a pivotal role in advancing drug development. It can also be applied to other areas, such as exploring the bioavailability of microplastics and food development. Some studies have found the presence of microplastics in the human body,<xref rid="prp21186-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> with the majority being absorbed through the intestines into the bloodstream. The inverted model can be used for validation and further exploration of this phenomenon.</p></sec><sec sec-type="conclusions" id="prp21186-sec-0056"><label>5</label><title>CONCLUSION</title><p>This study has successfully designed and optimized SNAC synthesis route that generates intermediate products with reduced production costs while ensuring safety, environmental sustainability, ease of experimental operation, and facilitation of purification processes, rendering it amenable for industrial&#8208;scale production. Additionally, it validates the absorption&#8208;enhancing effect of SNAC on PK, thereby enhancing its bioavailability within the body. This work lays a theoretical foundation for the development and subsequent research of second&#8208;class new drugs. At present, only male rats are conducted, and the study of gender differences can be continued in the future.</p></sec><sec id="prp21186-sec-0057"><title>AUTHOR CONTRIBUTIONS</title><p>All authors made substantial contributions to the design of this study, data acquisition and interpretation, statistical planning, drafting the article, or revising the article critically. All authors agree to be accountable for all aspects of the work and have approved the final version of the article for submission.</p></sec><sec id="prp21186-sec-0059"><title>FUNDING INFORMATION</title><p>None.</p></sec><sec sec-type="COI-statement" id="prp21186-sec-0060"><title>CONFLICT OF INTEREST STATEMENT</title><p>The authors declare that they have no conflicts of interest.</p></sec><sec id="prp21186-sec-0063"><title>ETHICS STATEMENT</title><p>Not applicable.</p></sec></body><back><ack id="prp21186-sec-0058"><title>ACKNOWLEDGMENTS</title><p>None.</p></ack><sec sec-type="data-availability" id="prp21186-sec-0062"><title>DATA AVAILABILITY STATEMENT</title><p>The datasets used and/or analyzed during this study are available from the corresponding author on reasonable request.</p></sec><ref-list content-type="cited-references" id="prp21186-bibl-0001"><title>REFERENCES</title><ref id="prp21186-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="prp21186-cit-0001"><string-name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></string-name>. <article-title>Clinical efficacy of Jinshuibao combined with pancreatic kininogenase in the treatment of diabetic nephropathy and its influence on renal function</article-title>. <source>J North Pharm</source>. <year>2019</year>;<volume>16</volume>(<issue>3</issue>):<fpage>25</fpage>&#8208;<lpage>26</lpage>.</mixed-citation></ref><ref id="prp21186-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="prp21186-cit-0002"><string-name name-style="western"><surname>Tuttle</surname><given-names>KR</given-names></string-name>, <string-name name-style="western"><surname>Bakirs</surname><given-names>GL</given-names></string-name>, <string-name name-style="western"><surname>Bilous</surname><given-names>RW</given-names></string-name>, et&#160;al. <article-title>Diabetic kidney disease: a report from an ADA consensus conference</article-title>. <source>Am J Kidney Dis</source>. <year>2014</year>;<volume>64</volume>(<issue>11</issue>):<fpage>792</fpage>&#8208;<lpage>802</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.ajkd.2014.08.001</pub-id><pub-id pub-id-type="pmid">25257325</pub-id></mixed-citation></ref><ref id="prp21186-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="prp21186-cit-0003"><string-name name-style="western"><surname>Xu</surname><given-names>XZ</given-names></string-name>, <string-name name-style="western"><surname>Tu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>CL</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>DW</given-names></string-name>. <article-title>Effect of human tissue type kallikrein gene on diabetic nephropathy in rats and its mechanism</article-title>. <source>Chin J Integr Tradit West Nephrol</source>. <year>2008</year>;<volume>9</volume>(<issue>6</issue>):<fpage>490</fpage>&#8208;<lpage>493</lpage>.</mixed-citation></ref><ref id="prp21186-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="prp21186-cit-0004"><string-name name-style="western"><surname>Yu</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Ha</surname><given-names>LD</given-names></string-name>. <article-title>Effect of pancreatic kininogenase on early diabetic nephropathy</article-title>. <source>Modern J Integr Tradit Chin West Med</source>. <year>2008</year>;<volume>17</volume>(<issue>34</issue>):<fpage>5311</fpage>.</mixed-citation></ref><ref id="prp21186-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="prp21186-cit-0005"><string-name name-style="western"><surname>Zhao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Duan</surname><given-names>LL</given-names></string-name>, <string-name name-style="western"><surname>Chao</surname><given-names>L</given-names></string-name>. <article-title>Effect of pancreatic kininogenase enteric&#8208;coated tablets combined with irbesartan tablets on TM,TNF&#8208;&#945;,IL&#8208;18 of type 2 diabetic nephropathy with hypertension</article-title>. <source>J Clin Exp Med</source>. <year>2021</year>;<volume>20</volume>(<issue>16</issue>):<fpage>1703</fpage>&#8208;<lpage>1707</lpage>.</mixed-citation></ref><ref id="prp21186-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="prp21186-cit-0006"><string-name name-style="western"><surname>Ferruzza</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Rossi</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Scarino</surname><given-names>mL</given-names></string-name>, et&#160;al. <article-title>A protocol for differentiation of human intestinal caco&#8208;2cells in asymmetric serum&#8208;containing medium</article-title>. <source>Toxicol In&#160;Vitro</source>. <year>2012</year>;<volume>26</volume>(<issue>8</issue>):<fpage>1252</fpage>&#8208;<lpage>1255</lpage>.<pub-id pub-id-type="pmid">22265977</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tiv.2012.01.008</pub-id></mixed-citation></ref><ref id="prp21186-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="prp21186-cit-0007"><string-name name-style="western"><surname>Fredlund</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Winiwarter</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hilgendorf</surname><given-names>C</given-names></string-name>. <article-title>In vitro intrinsic permeability: a transporter&#8208;independent measure of Caco&#8208;2 cell permeability in drug design and development</article-title>. <source>Mol Pharm</source>. <year>2017</year>;<volume>14</volume>(<issue>5</issue>):<fpage>1601</fpage>&#8208;<lpage>1609</lpage>.<pub-id pub-id-type="pmid">28329446</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.molpharmaceut.6b01059</pub-id></mixed-citation></ref><ref id="prp21186-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="prp21186-cit-0008"><string-name name-style="western"><surname>Ingels</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Beck</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Oth</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Augustijns</surname><given-names>P</given-names></string-name>. <article-title>Effect of simulated intestinal fluid on drug permeability estimation across caco&#8208;2 monolayers</article-title>. <source>Int J Pharm</source>. <year>2004</year>;<volume>274</volume>(<issue>1&#8211;2</issue>):<fpage>221</fpage>&#8208;<lpage>232</lpage>.<pub-id pub-id-type="pmid">15072798</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijpharm.2004.01.014</pub-id></mixed-citation></ref><ref id="prp21186-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="prp21186-cit-0009"><string-name name-style="western"><surname>Artursson</surname><given-names>P</given-names></string-name>. <article-title>Epithelial transport of drugs in cell culture: a model for studying the passive diffusion of drugs over intestinal absorptive(caco&#8208;2)cells</article-title>. <source>J Pharm Sci</source>. <year>1990</year>;<volume>79</volume>(<issue>6</issue>):<fpage>476</fpage>&#8208;<lpage>482</lpage>.<pub-id pub-id-type="pmid">1975619</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jps.2600790604</pub-id></mixed-citation></ref><ref id="prp21186-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="prp21186-cit-0010"><string-name name-style="western"><surname>Artursson</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Karlsson</surname><given-names>J</given-names></string-name>. <article-title>Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (caco&#8208;2) cells</article-title>. <source>Biochem Biophys Res Commun</source>. <year>1991</year>;<volume>175</volume>(<issue>3</issue>):<fpage>880</fpage>&#8208;<lpage>885</lpage>.<pub-id pub-id-type="pmid">1673839</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0006-291x(91)91647-u</pub-id></mixed-citation></ref><ref id="prp21186-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="prp21186-cit-0011"><string-name name-style="western"><surname>Lv</surname><given-names>XJ</given-names></string-name>, <string-name name-style="western"><surname>Cao</surname><given-names>YD</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>KY</given-names></string-name>. <article-title>Establishment and validation of Caco&#8208;2 cell in&#160;vitro absorption model</article-title>. <source>Herald Med</source>. <year>2018</year>;<volume>37</volume>(<issue>11</issue>):<fpage>1311</fpage>&#8208;<lpage>1315</lpage>.</mixed-citation></ref><ref id="prp21186-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="prp21186-cit-0012"><string-name name-style="western"><surname>Ming</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Thakker</surname><given-names>DR</given-names></string-name>. <article-title>Role of basolateral efflux transporter MRP4 in the intestinal absorption of the antiviral drug adefovir dipivoxil</article-title>. <source>Biochem Pharmacol</source>. <year>2010</year>;<volume>79</volume>(<issue>3</issue>):<fpage>455</fpage>&#8208;<lpage>462</lpage>.<pub-id pub-id-type="pmid">19735648</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bcp.2009.08.029</pub-id></mixed-citation></ref><ref id="prp21186-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="prp21186-cit-0013"><string-name name-style="western"><surname>Buckley</surname><given-names>ST</given-names></string-name>, <string-name name-style="western"><surname>Bkdal</surname><given-names>TA</given-names></string-name>, <string-name name-style="western"><surname>Vegge</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Transcellular stomach absorption of a derivatized glucagon&#8208;like peptide&#8208;1 receptor agonist</article-title>. <source>Sci Transl Med</source>. <year>2018</year>;<volume>10</volume>(<issue>467</issue>):<fpage>eaar7047</fpage>.<pub-id pub-id-type="pmid">30429357</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.aar7047</pub-id></mixed-citation></ref><ref id="prp21186-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="prp21186-cit-0014"><string-name name-style="western"><surname>Han</surname><given-names>KS</given-names></string-name>, <string-name name-style="western"><surname>Xie</surname><given-names>XL</given-names></string-name>, <string-name name-style="western"><surname>Tian</surname><given-names>SH</given-names></string-name>, et&#160;al. <article-title>Study on the ELISA double&#8208;antibody Sandwich method and pharmacokinetics of recombinant human calcineurin B subunit in rat plasma</article-title>. <source>China Pharm</source>. <year>2016</year>;<volume>27</volume>(<issue>25</issue>):<fpage>3</fpage>.</mixed-citation></ref><ref id="prp21186-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="prp21186-cit-0015"><string-name name-style="western"><surname>Roda</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Guardigli</surname><given-names>M</given-names></string-name>. <article-title>Analytical chemiluminescence and bioluminescence: latest achievements and new horizons</article-title>. <source>Anal Bioanal Chem</source>. <year>2012</year>;<volume>402</volume>(<issue>1</issue>):<fpage>69</fpage>&#8208;<lpage>76</lpage>.<pub-id pub-id-type="pmid">22002591</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00216-011-5455-8</pub-id></mixed-citation></ref><ref id="prp21186-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="prp21186-cit-0016"><string-name name-style="western"><surname>Dotsikas</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Loukas</surname><given-names>YL</given-names></string-name>. <article-title>Improved performance of antigen HRP conjugate&#8208;based immunoassays after the addition of anti&#8208;HRP antibody and application of a liposomal chemiluminescence marker</article-title>. <source>Anal Sci</source>. <year>2012</year>;<volume>28</volume>(<issue>8</issue>):<fpage>753</fpage>&#8208;<lpage>757</lpage>.<pub-id pub-id-type="pmid">22878629</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2116/analsci.28.753</pub-id></mixed-citation></ref><ref id="prp21186-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="prp21186-cit-0017"><string-name name-style="western"><surname>Wang</surname><given-names>CY</given-names></string-name>, <string-name name-style="western"><surname>Ji</surname><given-names>XQ</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>SN</given-names></string-name>, <string-name name-style="western"><surname>Leng</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>X</given-names></string-name>. <article-title>Determination of blood concentration of tacrolimus by EMIT vs ELISA</article-title>. <source>China Pharm</source>. <year>2014</year>;<volume>25</volume>(<issue>30</issue>):<fpage>2816</fpage>.</mixed-citation></ref><ref id="prp21186-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="prp21186-cit-0018"><string-name name-style="western"><surname>Stoll</surname><given-names>BR</given-names></string-name>, <string-name name-style="western"><surname>Leipold</surname><given-names>HR</given-names></string-name>, <string-name name-style="western"><surname>Milstein</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Edwards</surname><given-names>DA</given-names></string-name>. <article-title>A mechanistic analysis of carrier&#8208;mediated oral delivery of protein therapeutics</article-title>. <source>J Control Release</source>. <year>2000</year>;<volume>64</volume>(<issue>1</issue>):<fpage>217</fpage>&#8208;<lpage>228</lpage>.<pub-id pub-id-type="pmid">10640659</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0168-3659(99)00144-3</pub-id></mixed-citation></ref><ref id="prp21186-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="prp21186-cit-0019"><string-name name-style="western"><surname>mLynek</surname><given-names>GM</given-names></string-name>, <string-name name-style="western"><surname>Calvo</surname><given-names>LJ</given-names></string-name>, <string-name name-style="western"><surname>Robinson</surname><given-names>JR</given-names></string-name>. <article-title>Carrier&#8208;enhanced human growth hormone absorption across isolated rabbit intestinal tissue</article-title>. <source>Int J Pharm</source>. <year>2000</year>;<volume>197</volume>(<issue>1</issue>):<fpage>13</fpage>&#8208;<lpage>21</lpage>.<pub-id pub-id-type="pmid">10704789</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0378-5173(99)00322-1</pub-id></mixed-citation></ref><ref id="prp21186-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="prp21186-cit-0020"><string-name name-style="western"><surname>Stock</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Laurisch</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Franke</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Uptake and cellular effects of PE, PP, PET and PVC microplastic particles</article-title>. <source>Toxicol In&#160;Vitro</source>. <year>2021</year>;<volume>70</volume>(<issue>1</issue>):<fpage>10</fpage>&#8208;<lpage>50</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tiv.2020.105021</pub-id><pub-id pub-id-type="pmid">33049312</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>